At-home genetic tests scrutinized
This article was originally published in The Gray Sheet
"No at-home genetic tests have been reviewed by the FDA, and the FDA has not evaluated the accuracy of their claims," writes the Federal Trade Commission in a July 27 consumer fact sheet. FTC notes that at-home genetic tests, which range in price from $295 to $1,200, are not backed by "valid scientific studies" showing their safety and efficacy. "Because of the complexities involved in both the testing and the interpretation of the results, genetic tests should be performed in a specialized laboratory," with results interpreted by a clinician, the fact sheet notes. FTC has been criticized for its limited oversight of genetic testing claims (1"The Gray Sheet" Nov. 3, 2003, p. 16)...
You may also be interested in...
The Federal Trade Commission's limited oversight of regional laboratories and genetic test promotional claims for non-life-threatening diseases is eliciting concern from the HHS Secretary's Advisory Committee on Genetics, Health & Society
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.